

Attorney Docket No. HAR-001DV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Strominger et al.

SERIAL NO.:

08/991,628

GROUP NO.:

1642

#4 AR

FILING DATE:

November 5, 1997

EXAMINER:

Not yet assigned

07/04/98

TITLE:

Identification of Self and Non-Self Antigens Implicated In Autoimmune

Disease

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. §1.97, Applicants hereby make of record the references listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the references are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

\boxtimes	(1)	within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or
	(2)	after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and
		the requisite Statement is below, OR
		the requisite fee under Rule 1.17(p), namely \$240.00, is included herein, or
	(3)	after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, AND
		Applicant hereby Petitions the Commissioner to accept and consider the attached Information Disclosure Statement AND

Information Disclosure Statement Serial No.: Page 2 of 2 the requisite Statement is below, AND the requisite petition fee due under Rule 1.17(i)(I), namely \$130.00 is included herein. It is respectfully requested that each of the references shown on the attached Form PTO-1449 be made of record in this application. **STATEMENT** As required under §1.97(e), Applicants, through the undersigned, hereby state either that [check the appropriate space]: 1. [E]ach item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or 2. [N]o item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign

[N]o item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEE AUTHORIZATION

Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 20-0531. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

Date: June 8, 1998 Reg. No. 38,349

Tel. No.: (617) 248-7362 Fax No.: (617) 248-7100

395MJT6615/3.A603269-1

100pootiuity buomittou

Mighael J. Twontey Attorney for Applicants

Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110





PATENT Attorney Docket No. HAR-001DV

BECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICION 1 6 1998 ...

APPLICANTS:

Strominger et al.

SERVICE OF

SERIAL NO.:

08/991,628

GROUP NO.:

1642

FILING DATE:

November 5, 1997

EXAMINER:

Not yet assigned

TITLE:

Identification of Self and Non-Self Antigens Implicated In Autoimmune

Disease

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on this 8th day of June, 1998.

Christine M. Freniere

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith are: an Information Disclosure Statement, PTO Form 1449 (6 sheets) and copies of the cited references AA-AB, BA, and CA-DJ.